<DOC>
	<DOCNO>NCT01708161</DOCNO>
	<brief_summary>This multi-center , open-label , phase Ib/II study . The aim phase Ib part estimate MTD ( ) and/or identify recommended phase II dose ( ) ( RP2Ds ) combination BYL719 AMG 479 ( ganitumab ) , follow phase II part ass clinical efficacy assess safety combination select patient population . Patients treated progression disease , unacceptable toxicity develop , withdrawal informed consent , whichever occur first . All patient follow . At minimum , patient must complete safety follow-up assessment 30 day last dose study treatment .</brief_summary>
	<brief_title>A Phase Ib/II Study Combination BYL719 Plus AMG 479 Adult Patients With Selected Solid Tumors</brief_title>
	<detailed_description>This multi-center , open-label , phase Ib/II study . The aim phase Ib part estimate MTD ( ) and/or identify recommended phase II dose ( ) ( RP2Ds ) combination BYL719 AMG 479 ( ganitumab ) , follow phase II part ass clinical efficacy assess safety combination select patient population . The dose escalation part study guide Bayesian Logistic Regression Model ( BLRM ) . Once MTD/RP2D determine , patient enrol two Phase II arm . Patients PIK3CA mutate amplified hormone receptor positive breast carcinoma enrol Arm 1 ; patient PIK3CA mutate amplified ovarian carcinoma enrol Arm 2 . Patients treated progression disease , unacceptable toxicity develop , withdrawal informed consent , whichever occur first . All patient follow . At minimum , patient must complete safety follow-up assessment 30 day last dose study treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Written inform consent . Patients age â‰¥ 18 year ( male female ) . Patients follow histologically/cytologicallyconfirmed advanced solid tumor document somatic PIK3CA mutation amplification tumor tissue : Hormone receptor positive breast carcinoma Ovarian carcinoma Other tumor upon agreement sponsor Adequate organ function Negative serum pregnancy test Exclusion criterion : Patients know history severe infusion reaction monoclonal antibody . Patients primary CNS tumor CNS tumor involvement . History thromboembolic event require fulldose anticoagulation therapy time prior enrollment . Clinically significant cardiac disease . History another malignancy within last 2 year . Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PIK3CA mutation</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
</DOC>